<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">epidemiology</journal-id><journal-title-group><journal-title xml:lang="ru">Эпидемиология и Вакцинопрофилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Epidemiology and Vaccinal Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-3046</issn><issn pub-type="epub">2619-0494</issn><publisher><publisher-name>«Numicom» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31631/2073-3046-2022-21-3-96-106</article-id><article-id custom-type="elpub" pub-id-type="custom">epidemiology-1564</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Современное состояние методов оценки безопасности и эффективности дифтерийного и столбнячного компонентов комбинированных вакцин</article-title><trans-title-group xml:lang="en"><trans-title>Current state of methods for control the safety and potency of diphtheria toxoid and tetanus toxoid in combined vaccines</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9035-6072</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Комаровская</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Komarovskaya</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Игоревна Комаровская  – ведущий эксперт лаборатории анатоксинов и антитоксических препаратов</p><p>127051, Москва, Петровский б-р, д. 8, стр. 2</p><p>+7 (499) 190-18-18 (64-08)</p></bio><bio xml:lang="en"><p>Elena I. Komarovskaya  – Leading Expert of the Laboratory for Toxoids and Antitoxic Sera</p><p>8, Petrovsky Boulevard, building 2, Moscow, 127051</p><p>+7 (499) 190-18-18, add. 6408</p></bio><email xlink:type="simple">Komarovskaya@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5029-3751</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Перелыгина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Perelygyna</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Викторовна Перелыгина – к. м. н., начальник лаборатории анатоксинов и антитоксических препаратов</p><p>127051, Москва, Петровский б-р, д. 8, стр. 2</p><p>+7 (499) 190-18-18 (64-15)</p></bio><bio xml:lang="en"><p>Olga V. Perelygina – Cand. Sci. (Med.), Head of the laboratory for Toxoids and Antitoxic Sera</p><p>8, Petrovsky Boulevard, building 2, Moscow, 127051</p><p>+7 (499) 190-18-18 (64-08)</p></bio><email xlink:type="simple">Pereligina@expmed.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Centre for Expert Evaluation of Medicinal Products</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>10</day><month>07</month><year>2022</year></pub-date><volume>21</volume><issue>3</issue><fpage>96</fpage><lpage>106</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Комаровская Е.И., Перелыгина О.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Комаровская Е.И., Перелыгина О.В.</copyright-holder><copyright-holder xml:lang="en">Komarovskaya E.I., Perelygyna O.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epidemvac.ru/jour/article/view/1564">https://www.epidemvac.ru/jour/article/view/1564</self-uri><abstract><p>Актуальность. Разработка и внедрение методов оценки эффективности (иммуногенности) и безопасности дифтерийного и столбнячного анатоксинов, входящих в состав комбинированных вакцин в календарях профилактических прививок, интенсивно проводившиеся в 1920–1970 гг., в настоящее время снова приобрели актуальность. В последние десятилетия производители вакцин, следуя концепции 3Rs (Replacement, Reduction, Refinement – замена, сокращение, усовершенствование) проводят исследования по усовершенствованию существующих методов. В отношении определения иммуногенности вакцин внимание исследователей направлено на внедрение методов, исключающих оценку устойчивости иммунизированных животных к введению летальных доз токсинов («золотой стандарт»), а также уменьшению количества животных в испытаниях. При оценке безопасности вакцин некоторые производители считают достаточно убедительными испытания, проведенные на определенных стадиях процесса производства, и исключают проверку конечного продукта на безопасность. Цель обзора. Провести сравнительный анализ современных методов контроля безопасности и эффективности (специфической активности) дифтерийного и столбнячного анатоксинов. Выводы. Анализ нормативных документов и руководств, касающихся оценки безопасности и методов определения иммуногенности дифтерийного и столбнячного анатоксинов на всех стадиях производства, Всемирной организации здравоохранения, Евросоюза, США и Японии показал, что в Российской Федерации действуют требования, аналогичные международным. Более того, в отношении методов для выявления реверсии токсичности применяют наиболее чувствительные методы и более жесткие критерии приемлемости опыта. Сопоставление характеристик различных методов позволяет сделать заключение о необходимости гармонизации отечественных и международных методов оценки безопасности и иммуногенности дифтерийного и столбнячного анатоксинов, что даст возможность не только облегчить регистрацию зарубежных вакцин в России, но и ускорить регистрацию отечественных вакцин в других странах.</p></abstract><trans-abstract xml:lang="en"><p>Relevance. Diphtheria toxoid (DT) and tetanus toxoid (TT) manufacturing appears as many steps process. On every stage of proceeding vaccine the control of critical points is being provided. The Parke Williams 8 strain of Corynebacterium diphtheriae used in Russia for producing DT, Clostridium tetani strain Harvard – for TT. Each culture's supernatant proceed being estimated in relevance of toxoid potency via in vivo and/or in vitro methods. To produce DT, the activity of the toxoid must be not less than 50 Lf/ml and 40 Lf/ml for TT. Toxoids must fit in the main safety conditions – absence of toxin and reversion to toxicity impossibility. In accordance with WHO recommendations, five guinea pigs are injected subcutaneously with at least 500 Lf/ml of purified diphtheria toxoid, animals are observed for 42 days. By the end of observation period not the least than 80% of animals must remain alive without diphtheria intoxication (red adrenals). In Russia WHO approach was modified: guinea pigs are injected subcutaneously with purified diphtheria toxoid at a dose of at least 1500 Lf. During 42 days long observation period weight loss and animals dies must not appear. In case of death purified DT is not applicable. TT specific safety control is also carried out on guinea pigs. In accordance with WHO recommendations, five animals are injected subcutaneously with 500 Lf of purified TT. The animals are observed for 21 days daily, noting clinical signs of tetanus. If during the entire observation period no tetanus symptoms are observed in a single guinea pig and after the entire observation period 80% of the animals survives, tetanus toxoid is considered suitable for use. In Russia, the test for the absence of tetanus toxin is carried out similarly, excepting tetanus toxoid dose, which is 1500 Lf. The suitability criteria for purified TT are the absence of clinical signs of tetanus intoxication, weight loss and death of animals throughout entire observation period. Toxicity reversion tests are also provided. WHO considers guinea pig intradermal test to be suitable method for detecting diphtheria toxin, while guinea-pig methods are preferred for tetanus toxin, due to mice less sensitivity to tetanus toxin. In Russia, the most sensitive methods are used to detect the presence of toxins: intradermal administration to two guinea pigs in a volume of 0.1 ml or to one rabbit in a volume of 0.2 ml when testing diphtheria toxoid. Within four days, local reactions must not appear at the injection site. In the event of reactions, hence reversal of toxicity, the substance is rejected. When testing tetanus toxoid, five guinea pigs are injected subcutaneously into both sides of ten single human doses. Animals should be free of clinical signs of tetanus for 21 days after injection. Diphtheria and tetanus toxoids, after adsorption to a suitable adjuvant are monitored for specific safety. In accordance with WHO recommendations, at least 5 single human doses are administered subcutaneously to five guinea pigs. In case of testing adsorbed diphtheria toxoid, animals are observed for 42 days, tetanus toxoid – 21 days. The criteria for evaluating the suitability of adsorbed DT and TT are similar: during the entire observation period, animals should not show signs of diphtheria or tetanus intoxication; at the end of the observation period, at least 80% of the animals remain alive. In Russia, to test adsorbed DT and TT, five guinea pigs are injected subcutaneously with 10 single human doses. The duration of observation of animals in the DT test is 21 days, in the TT test – 30 days. The drug is considered to have passed the test if, during the entire observation period, the animals did not experience weight loss, signs of tetanus or, respectively, diphtheria intoxication, and all animals remained alive. In the event of the death of at least one animal in both cases from specific intoxication, the drug is considered not to have passed the test. Modern identifying potency (immunogenicity) of diphtheria toxoid and tetanus toxoid tests are based on determining immunized animals resistance for administration challenge toxin or evaluation of protective antibodies level in serum. In Russia to assess the potency of diphtheria toxoid (DT) and tetanus toxoid the challenge lethal method has been used for more than 60 years, challenge is based on determination of potency via its possibility to defend immunized animals from lethal doses of toxins. This method is used as «golden standard». The analysis of normative documents and guidelines of the World Health Organization, the European Union, the USA and Japan, concerning the issues of safety assessment and methods for determining the immunogenicity of diphtheria and tetanus toxoids at all stages of production, was carried out. It has been established that the approach adopted in the Russian Federation meets all international requirements. Moreover, with regard to methods for detecting reversion of toxicity, the most sensitive methods and more stringent criteria for the acceptance of experience are applied. The review presents data on methods for determining the immunogenicity of vaccines for the prevention of diphtheria and tetanus in the world. The advantages and disadvantages of some methods are reflected. The results of the analysis of these methods allow us to conclude that it is necessary to harmonize domestic and international methods for assessing the safety and immunogenicity of diphtheria and tetanus toxoids, which will make it possible not only to facilitate the registration of foreign vaccines in Russia, but also to speed up the registration of domestic vaccines in other countries.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>специфическая безопасность</kwd><kwd>реверсия токсичности</kwd><kwd>дифтерийный анатоксин</kwd><kwd>столбнячный анатоксин</kwd><kwd>иммуногенность</kwd><kwd>специфическая активность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>specific toxicity</kwd><kwd>reversion to toxicity</kwd><kwd>diphtheria toxoid</kwd><kwd>tetanus toxoid</kwd><kwd>potency assay</kwd><kwd>safety</kwd><kwd>efficacy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Plotkin SL, Plotkin SA. A Short History of Vaccination. In: Plotkin SA, Walter AO, Paul AO, et al. Plotkin’s Vaccines, 7th ed. Philadelphia, PA : Elsevier, [2018] ©2018 eBook. P. 1–15.</mixed-citation><mixed-citation xml:lang="en">Plotkin SL, Plotkin SA. A Short History of Vaccination. In:  Plotkin SA, Walter AO, Paul AO, et al. Plotkin’s Vaccines, 7th ed. Philadelphia, PA : Elsevier, [2018] ©2018 eBook. P. 1–15. </mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tejpratap SP, Wharton T, Wharton M. Diphtheria Toxoid. In: Plotkin SA, Walter AO, Paul AO, et al. Plotkin’s Vaccines, 7th ed. Philadelphia, PA : Elsevier, [2018] ©2018 eBook. P. 261–275.</mixed-citation><mixed-citation xml:lang="en">Tejpratap SP, Wharton T, Wharton M. Diphtheria Toxoid. In:  Plotkin SA, Walter AO, Paul AO, et al. Plotkin’s Vaccines, 7th ed. Philadelphia, PA : Elsevier, [2018] ©2018 eBook. P. 261–275. </mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Roper MH., Wassilak SGF, Scobie HM, et al. Tetanus Toxoid. In: Plotkin SA, Walter AO, Paul AO et al. Plotkin’s Vaccines, 7th ed. Philadelphia, PA : Elsevier, [2018] ©2018 eBook. P. 1052 –1079.</mixed-citation><mixed-citation xml:lang="en">Roper MH., Wassilak SGF, Scobie HM et all. Tetanus Toxoid In:  Plotkin SA, Walter AO, Paul AO, et al. Plotkin’s Vaccines, 7th ed. Philadelphia, PA: Elsevier, [2018] ©2018 eBook. P. 1052–1079. </mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 9th report: WHO TRS N°108: 1955.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 9th report: WHO TRS N°108: 1955.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 16th report: WHO TRS N°274: 1963.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 16th report: WHO TRS N°274: 1963.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 17th report: WHO TRS N°293: 1964.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 17th report: WHO TRS N°293: 1964.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 16th report: WHO TRS N°329: 1965.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 16th report: WHO TRS N°329: 1965.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 30th report: WHO TRS N°638: 1979.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 30th report: WHO TRS N°638: 1979.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 17th report: WHO TRS N°800: 1990. Annex 2. Requirements for diphtheria, tetanus, pertussis and combined vaccines.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 17th report: WHO TRS N°800: 1990. Annex 2. Requirements for diphtheria, tetanus, pertussis and combined vaccines.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 17th report: WHO TRS N°927: 2005. Annex 5. Recommendations for diphtheria, tetanus, pertussis and combined vaccines (Amendments 2003).</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 17th report: WHO TRS N°927: 2005. Annex 5. Recommendations for diphtheria, tetanus, pertussis and combined vaccines (Amendments 2003).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Manual for Quality Control of Diphtheria, Tetanus and PertussisVaccines, World Health Organization 2013. Ordering code: WHO/IVB/11.11.</mixed-citation><mixed-citation xml:lang="en">Manual for Quality Control of Diphtheria, Tetanus and PertussisVaccines, World Health Organization 2013.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Сорок пятая сессия Всемирной ассамблеи здравоохранения: Женева, 4-14 Мая 1992 г.: резолюции и решения: приложения. Всемирная организация здравоохранения. Номер документа: WHA45/1992/REC/1. Доступно на: https://apps.who.int/iris/handle/10665/203139. Ссылка активна на 12 декабря 2021.</mixed-citation><mixed-citation xml:lang="en">Forty-fifth World Health Assembly resolutions and decisions, annexes Geneva, 4-14 May 1992. Number of document WHA45/1992/REC/1. World Health Organization. Available at: https://apps.who.int/iris/handle/10665/203139 Accessed: 12 Dec 2021 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева И. А., Перелыгина О. В., Колышкина Е. Д. Оценка стабильности производства коклюшного, дифтерийного и столбнячного компонентов АКДС-вакцины с помощью контрольных карт Шухарта. БИОпрепараты. Профилактика, диагностика, лечение. 2021;21(4):256–265. https://doi.org/10.30895/2221-996X-2021-21-4-256-265</mixed-citation><mixed-citation xml:lang="en">Alekseeva IA, Perelygina OV, Kolyshkina ED. Estimation of production consistency of diphtheria, tetanus, and pertussis components of the DTP vaccine using Shewhart charts BIOpreparations. Prevention, Diagnosis, Treatment. 2021;21(4):256–265 (In Russ.). doi.org/10.30895/2221-996X-2021-21-4-256-265</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Гаврилова Н. А., Олефир Ю. В., Меркулов В. А. и др. Взаимозаменяемость вакцин: проблемы и перспективы. БИОпрепараты. Профилактика, диагностика, лечение. 2021;21(3):142-157. https://doi.org/10.30895/2221-996X-2021-21-3-142-157</mixed-citation><mixed-citation xml:lang="en">Gavrilova N.A., Olefir Yu.V., et al. Vaccine interchangeability: problems and prospects.  BIOpreparations. Prevention, Diagnosis, Treatment. 2021;21(3):142–157 (In Russ.).  doi.org/10.30895/2221-996X-2021-21-3-142-157</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 40th report: WHO TRS N°800: 1989.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO Expert Committee on Biological Standardization. Technical Report Series. 40th report: WHO TRS N°800: 1989.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Каталог штаммов, выпуск пятый, Clostridia. Кравченко А. Т., Черткова Ф. А., ред. Государственный контрольный институт медицинских биологических препаратов им. Л. А. Тарасевича. Москва; 1963.</mixed-citation><mixed-citation xml:lang="en">Strains catalog, fifth issue, Clostridia. Ed.: Kravchenko A.T., CHertkova F.A. State Control Institute of Medical Biological Products named after L.A. Tarasevich. Moscow; 1963 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Фармакопейная статья 3.3.1.0010.15 Вакцина коклюшно-дифтерийно-столбнячная адсорбированная, Государственная фармакопея Российской Федерации. XIV изд. Т.4; 2018.</mixed-citation><mixed-citation xml:lang="en">Pharmacopoeia monograph 3.3.1.0010.15 Pertussis (whole cell)-diphtheria-tetanus vaccine, adsorbed. The State Pharmacopoeia of Russian Federation 14 ed. Р. 4. Moscow; 2018 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Фармакопейная статья 3.3.1.0002.15 Анатоксин дифтерийно-столбнячный адсорбированный (АДС-анатоксин), Государственная фармакопея Российской Федерации. XIII изд. Т.3; 2015.</mixed-citation><mixed-citation xml:lang="en">Pharmacopoeia monograph 3.3.1.0002.15 Diphtheria-tetanus vaccine, adsorbed. The State Pharmacopoeia of Russian Federation 13 ed. Р. 3. Moscow; 2015 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Diphtheria and Tetanus vaccine (adsorbed), version 01/2021:0444. Ph. Eur. 10th Edition. Strasbourg, France: Council of Europe; European Pharmacopoeia online, www.pheur.edqm.eu/home</mixed-citation><mixed-citation xml:lang="en">Diphtheria and Tetanus vaccine (adsorbed), version 01/2021:0444. Ph. Eur. 10th Edition. Strasbourg, France: Council of Europe; European Pharmacopoeia online. Available at: www.pheur. edqm.eu/home</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">The National Institute for Biological Standards and Control (NIBSC) [Электронный ресурс] URL: https://www.nibsc.org/documents/ifu/98-572.pdf</mixed-citation><mixed-citation xml:lang="en">The National Institute for Biological Standards and Control (NIBSC). Available at: https://www.nibsc.org/documents/ifu/98-572.pdf</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Общая фармакопейная статья 1.7.2.0003.15 Иммуногенность адсорбированного дифтерийного анатоксина, Государственная фармакопея Российской Федерации. XIV изд. Т.2; 2018.</mixed-citation><mixed-citation xml:lang="en">General pharmacopoeia monograph 1.7.2.0003.15. Potency assay of diphtheria vaccine (adsorbed). The State Pharmacopoeia of Russian Federation 14 ed. Р. 2. Moscow; 2018 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Общая фармакопейная статья 1.7.2.0004.15 Иммуногенность адсорбированного столбнячного анатоксина, Государственная фармакопея Российской Федерации. XIV изд. Т.2; 2018.</mixed-citation><mixed-citation xml:lang="en">General pharmacopoeia monograph 1.7.2.0004.15. Potency assay of tetanus vaccine (adsorbed). The State Pharmacopoeia of Russian Federation 14 ed. Р. 2. Moscow; 2018 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Фармакопейная статья 3.3.1.0003.15 Анатоксин дифтерийно-столбнячный адсорбированный с уменьшенным содержанием антигенов (АДС-М-анатоксин), Государственная фармакопея Российской Федерации. XIV изд. Т.4; 2018.</mixed-citation><mixed-citation xml:lang="en">Pharmacopoeia monograph 3.3.1.0003.15 Diphtheria and tetanus vaccine (adsorbed, reduced antigens content). The State Pharmacopoeia of Russian Federation 14 ed. Р. 4. Moscow; 2018 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Фармакопейная статья 3.3.1.0004.15 Анатоксин дифтерийный адсорбированный с уменьшенным содержанием антигена (АД-М-анатоксин), Государственная фармакопея Российской Федерации. XIV изд. Т.4; 2018.</mixed-citation><mixed-citation xml:lang="en">Pharmacopoeia monograph 3.3.1.0004.15 Diphtheria vaccine (adsorbed, reduced antigens content). The State Pharmacopoeia of Russian Federation 14 ed. Р. 4. Moscow; 2018 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Assay of diphtheria vaccine (adsorbed), general chapter 2.7.6 version 01/2008:20706. Ph. Eur. 10th Edition. Strasbourg, France: Council of Europe; European Pharmacopoeia online, www.pheur.edqm.eu/home</mixed-citation><mixed-citation xml:lang="en">Assay of diphtheria vaccine (adsorbed), general chapter 2.7.6 version 01/2008:20706. Ph. Eur. 10th Edition. Strasbourg, France: Council of Europe; European Pharmacopoeia online. Available at: www.pheur.edqm.eu/home.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Assay of tetanus vaccine (adsorbed), general chapter 2.7.8 version 01/2008:20708. Ph. Eur. 10th Edition. Strasbourg, France: Council of Europe; European Pharmacopoeia online, www.pheur.edqm.eu/home</mixed-citation><mixed-citation xml:lang="en">Assay of tetanus vaccine (adsorbed), general chapter 2.7.8 version 01/2008:20708. Ph. Eur. 10th Edition. Strasbourg, France: Council of Europe; European Pharmacopoeia online. Available at: www.pheur.edqm.eu/home</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Minimum requirements for biological products National Institute of Infectious Diseases Japan, 2006. https://ntp.niehs.nih.gov/iccvam/methods/biologics/vaccine/japan-minreqs.pdf</mixed-citation><mixed-citation xml:lang="en">Minimum requirements for biological products National Institute of Infectious Diseases Japan, 2006. Available at: https://ntp.niehs.nih.gov/iccvam/methods/biologics/vaccine/japanminreqs.pdf</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO Expert Committee on Biological Standardization. WHO/BS/09.2123. Collaborative Study: Calibration of Replacement WHO International Standard for Diphtheria Toxoid Adsorbed.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO Expert Committee on Biological Standardization. WHO/BS/09.2123. Collaborative Study: Calibration of Replacement WHO International Standard for Diphtheria Toxoid Adsorbed.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. WHO Expert Committee on Biological Standardization. WHO/BS/10.2150. International Collaborative Study: Calibration of Replacement WHO International Standard for Tetanus Toxoid Adsorbed.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. WHO Expert Committee on Biological Standardization. WHO/BS/10.2150. International Collaborative Study: Calibration of Replacement WHO International Standard for Tetanus Toxoid Adsorbed.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
